Patents by Inventor Antonios Danikas

Antonios Danikas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ester Imaging Agents
    Publication number: 20140213899
    Abstract: The present invention relates to contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents are esters of 5-aminolevulinic acid (5-ALA). They are useful in the diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, and for follow up of treatment of oesophageal cancer and Barrett's oesophagus. The contrast agents are delivered by particular routes of administration.
    Type: Application
    Filed: March 31, 2014
    Publication date: July 31, 2014
    Applicant: Photocure ASA
    Inventors: Antonios Danikas, Morten Eriksen
  • Therapy selection method
    Patent number: 8568693
    Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 29, 2013
    Assignee: GE Healthcare AS
    Inventors: Antonios Danikas, Clifford Smith, Ian A Wilson
  • METHOD FOR DETECTING DYSPLASIA
    Publication number: 20110268660
    Abstract: The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over Her2. The vector is labelled with an optical reporter suitable for in vivo imaging using light in the green to near-infrared wavelength 500-1200 nm. Also provided are novel optical imaging agents suitable for use in the method.
    Type: Application
    Filed: August 14, 2009
    Publication date: November 3, 2011
    Inventors: Antonios Danikas, Benedicte Guilbert
  • THERAPY SELECTION METHOD
    Publication number: 20110002849
    Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.
    Type: Application
    Filed: February 26, 2009
    Publication date: January 6, 2011
    Inventors: Antonios Danikas, Clifford Smith, Ian A. Wilson
  • ESTER IMAGING AGENTS
    Publication number: 20110004098
    Abstract: The present invention relates to contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents are esters of 5-aminolevulinic acid (5-ALA). They are useful in the diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, and for follow up of treatment of oesophageal cancer and Barrett's oesophagus. The contrast agents are delivered by particular routes of administration.
    Type: Application
    Filed: March 3, 2009
    Publication date: January 6, 2011
    Inventors: Antonios Danikas, Morten Eriksen